Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2016)
Stable 16-year storage of DNA purified with the QIAamp® DNA Blood Mini Kit. Application note QIAGEN GmbH
M. Berglund, U. Thunberg, G. Roos, R. Rosenquist, G. Enblad (2005)
The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma.Blood, 105 12
R. Sami, A. Nasr, Noha Ibrahim, Dalia Darweesh, Noha Hussieny (2012)
Association of IL-10 gene promoter polymorphisms and non-Hodgkin lymphoma in Egyptian patients, relation to susceptibility, correlation with survivalComparative Clinical Pathology, 21
Lennartz K Hartmann C (2016)
Stable 16-year storage of DNA purified with the QIAamp® DNA Blood Mini Kit
E. Domingo-Domènech, Y. Benavente, E. González-Barca, C. Montalbán, J. Gumà, R. Bosch, Sophia Wang, Q. Lan, D. Whitby, A. Sevilla, N. Rothman, S. Sanjosé (2007)
Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasmsHaematologica, 92
E. Lech-Maranda, L. Baseggio, J. Bienvenu, C. Charlot, F. Berger, D. Rigal, K. Warzocha, B. Coiffier, G. Salles (2004)
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.Blood, 103 9
J. Blay, N. Burdin, F. Rousset, G. Lenoir, P. Biron, T. Philip, J. Banchereau, M. Favrot (1993)
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.Blood, 82 7
(2016)
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.The Lancet. Oncology, 17 6
B. Eichhorst, M. Dreyling, T. Robak, E. Montserrat, M. Hallek (2011)
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 22 Suppl 6
E. Lech-Maranda, W. Młynarski, O. Grzybowska‐Izydorczyk, M. Borowiec, A. Pastorczak, B. Cebula-Obrzut, Gabriela Klimkiewicz-Wojciechowska, Monika Wcislo, M. Majewski, Aleksandra Kotkowska, T. Robak, K. Warzocha (2013)
Polymorphisms of TNF and IL‐10 genes and clinical outcome of patients with chronic lymphocytic leukemiaGenes, 52
M. Hallek, B. Cheson, D. Catovsky, F. Caligaris‐cappio, G. Dighiero, H. Döhner, P. Hillmen, M. Keating, E. Montserrat, K. Rai, T. Kipps (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.Blood, 111 12
A. Hochhaus, Susanne Saußele, G. Rosti, F. Mahon, J. Janssen, H. Hjorth-Hansen, J. Richter, C. Buske (2010)
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 26 Suppl 5
H. Rahman, M. Khorshied, O. Khorshid, H. Mourad (2017)
Association of Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms with B-Cell Non-Hodgkin Lymphoma in a Cohort of EgyptiansTurkish Journal of Hematology, 35
P. Murray (2007)
The JAK-STAT Signaling Pathway: Input and Output Integration1The Journal of Immunology, 178
K. Rai, A. Sawitsky, E. Cronkite, A. Chanana, R. Levy, B. Pasternack (1975)
Clinical staging of chronic lymphocytic leukemia.Blood, 46 2
Y. Herishanu, B. Katz, A. Lipsky, A. Wiestner (2013)
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Hematology/oncology clinics of North America, 27 2
R. Sabat, G. Grütz, Katarzyna Warszawska, Stefan Kirsch, Ellen Witte, K. Wolk, J. Geginat (2010)
Biology of interleukin-10.Cytokine & growth factor reviews, 21 5
(2016)
Stable 16-year storage of DNA purified with the QIAamp® DNA Blood Mini Kit. Application note QIAGEN GmbH, QIAGEN Straße
(2018)
Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
L. Cervenak, L. Morbidelli, D. Donati, S. Donnini, T. Kambayashi, J. Wilson, H. Axelson, E. Castaños-Vélez, H. Ljunggren, R. Malefyt, H. Granger, M. Ziche, M. Bejarano (2000)
Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.Blood, 96 7
H. Groux, M. Bigler, J. Vries, M. Roncarolo (1998)
Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells.Journal of immunology, 160 7
T. Hamblin (2009)
Just exactly how common is CLL?Leukemia research, 33 11
(2000)
Abolished antigenicity and tumorigenicity of Burkitt lymphoma by interleukin
W. Ouyang, S. Rutz, N. Crellin, P. Valdez, S. Hymowitz (2011)
Regulation and functions of the IL-10 family of cytokines in inflammation and disease.Annual review of immunology, 29
V. Ovsepyan, A. Gabdulkhakova, A. Shubenkiva, E. Zotina (2015)
Role of Interleukin-10 Gene Promoter Region Polymorphism in the Development of Chronic Lymphoid LeukemiaBulletin of Experimental Biology and Medicine, 160
N. Schoof, J. Franklin, R. Fürst, T. Zander, F. Bonin, F. Peyrade, L. Trümper, V. Diehl, A. Engert, D. Kube, D. Ré (2013)
Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma.The oncologist, 18 1
G. Trinchieri (2007)
Interleukin-10 production by effector T cells: Th1 cells show self controlThe Journal of Experimental Medicine, 204
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Abstract Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among western population. Many interesting reports suggest the role of IL-10 polymorphisms in CLL oncogenesis. This study aimed to study the relation between IL-10 (rs1800896)-1082 (G/A) gene polymorphism and the risk of development of B cell chronic lymphocytic leukemia and its impact on the patient outcome. IL-10 (rs1800896)-1082 (G/A) gene polymorphism was assessed in fifty patients with chronic lymphocytic leukemia as well as 50 age and sex-matched apparently healthy controls using polymerase chain reaction (PCR). The IL-10 (rs1800896) AG hetero, GG homo, AG + GG genotypes, and G allele showed significantly higher frequency (P > 0.001) in CLL cases when compared to control groups. The genotype AG + GG were significantly associated with advanced stages (P > 0.001), short time to first treatment (TFT) (P = 0.032), shorter progression free survival (PFS) (P = 0.044), and lower response to treatment (P = 0.003) as compared to wild genotype (AA wild). The IL-10 (rs1800896) genotypes (GG, AG) might have a role in the pathogenesis of CLL and have deleterious impact on the CLL patient’s outcome.
Comparative Clinical Pathology – Springer Journals
Published: Aug 1, 2020
Keywords: Pathology; Hematology; Oncology
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.